Welcome to our dedicated page for Aspire Biopharma Holdings SEC filings (Ticker: ASBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aspire Biopharma Holdings, Inc. (ASBP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑assisted context to help interpret complex documents. Aspire Biopharma is a Delaware‑incorporated biotechnology and biopharmaceutical company focused on a patent‑pending sublingual delivery platform for drugs and supplements, and its filings reflect both scientific ambitions and capital markets activity.
Through its registration statements on Form S‑1 and related amendments, Aspire details the structure of its convertible promissory notes, share registration for resale, and its status as a smaller reporting company and emerging growth company. Current reports on Form 8‑K describe material events such as the establishment and termination of an equity line of credit, recent sales of unregistered securities, changes in independent registered public accounting firms, and notices from Nasdaq regarding bid price and market value listing requirements.
Other filings, including the definitive proxy statement on Schedule 14A, outline shareholder proposals related to a reverse stock split, approval of share issuances under Nasdaq rules for the convertible notes, and potential adjournments to secure sufficient votes. These documents provide insight into how Aspire Biopharma manages its capital structure, maintains exchange listing compliance and seeks shareholder authorization for key corporate actions.
On this page, users can review ASBP’s 10‑K and 10‑Q reports when available for a fuller view of financial condition, risk factors and operational progress around its sublingual aspirin program, BUZZ BOMB™ supplement activities and broader pipeline. AI‑powered summaries highlight important terms in lengthy filings, explain the practical implications of financing arrangements, and surface notable items in Forms 3, 4 and 5 related to insider ownership and trading. Real‑time updates from EDGAR ensure that new Aspire Biopharma filings, amendments and exhibits are added as they are released, helping investors and researchers follow the company’s regulatory history efficiently.
Aspire Biopharma Holdings, Inc. is asking shareholders to approve the issuance of warrants and the shares issuable upon their exercise, including any Warrant Shares that would exceed 19.99% of outstanding common stock, and to ratify (i) adjustments to the number of shares issuable under the warrants and (ii) voluntary reductions of the warrants' exercise price of $0.00001 per share. The meeting record date is April 13, 2026 and shares outstanding were 5,024,142 as of that date. The Company also seeks authorization to adjourn the meeting to solicit additional proxies if necessary.
Aspire Biopharma Holdings, Inc. closed a $21.0 million private placement and strengthened its balance sheet while pursuing a major acquisition. The company completed the second and final tranche of its Series A Convertible Preferred Stock financing, issuing 12,500 shares for $10.0 million, bringing total proceeds to $21.0 million and lifting stockholders’ equity above the $2.5 million Nasdaq Capital Market minimum. Aspire plans to use the cash for working capital, to help fund the proposed acquisition of Dura Control Systems (DCS), and for general corporate purposes. It has a Letter of Intent to buy 100% of DCS, which generated more than $20 million in Adjusted EBITDA on over $200 million of 2025 revenue, for a $30 million all-cash purchase price. To finance this, Aspire obtained a commitment letter for a senior secured credit facility of up to $22.5 million on a five-year term at an interest rate 325 basis points above the one‑month term Secured Overnight Financing Rate.
Aspire Biopharma Holdings, Inc. completed a private placement Offering of 25,000 shares of Series A Convertible Preferred Stock for gross proceeds of about $21,000,000, split across two tranches. The first tranche closed on February 6, 2026 for 13,750 shares and $11,000,000, including conversion of $943,801 of existing debt.
On April 15, 2026, the company closed the second tranche for 12,500 shares and approximately $10,000,000 in gross proceeds. Net proceeds are intended to fund the cash component of a proposed Dura Driver Control Systems acquisition and for general corporate purposes. The company also filed a Certificate of Amendment designating 30,000 shares of Series A Convertible Preferred Stock with a par value of $0.0001 and stated value of $1,000 per share.
Aspire Biopharma Holdings, Inc. completed a private Offering of Series A Convertible Preferred Stock and amended the terms of this preferred class. The company has now issued 13,750 preferred shares for gross proceeds of $11,000,000 at the initial closing and an additional 12,500 preferred shares for $10,000,000 at a second closing on April 15, 2026.
Each preferred share has a stated value of $1,000 and is convertible into common stock at a price equal to 80% of the lowest closing price over five recent trading days, but not below a floor equal to 20% of the Nasdaq “Minimum Price,” subject to adjustments. Conversions are capped so that an investor generally cannot beneficially own more than 4.99% of outstanding common stock, adjustable up to 9.99% with notice.
The Certificate of Designation was amended on April 13, 2026 to designate 30,000 Series A preferred shares. Aspire states that, as a result of the Offering, it believes stockholders’ equity now exceeds $2.5 million, meeting the minimum requirement for continued listing on The Nasdaq Capital Market, and it awaits Nasdaq’s formal confirmation.
Aspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on April 10, 2026, where a quorum of stockholders voted on several proposals. The 8-K reports that all matters presented at the meeting were approved based on the tabulated voting results.
The disclosed proposals received votes in favor ranging from 1,466,141 to 2,096,356, with varying levels of opposition, abstentions, and broker non-votes. The filing confirms the outcomes of these stockholder votes and is signed by Chief Executive Officer Kraig Higginson.
Aspire Biopharma Holdings, Inc. has signed a non-binding Letter of Intent to acquire Dura Driver Control Systems (DCS), a tier-one automotive and industrial systems supplier. Aspire expects to buy 100% of DCS for $30 million in cash, subject to due diligence and a definitive agreement.
For the fiscal year ended December 31, 2025 (unaudited), DCS generated more than $200 million in revenue, over $17 million in net income and over $22 million in Adjusted EBITDA. DCS supplies mechatronic actuators, human‑machine interfaces, industrial cables and control systems, backed by more than 310 patents and 11 manufacturing facilities worldwide.
The contemplated acquisition would diversify Aspire beyond biopharmaceutical drug delivery technology into a higher‑revenue industrial and automotive platform. The company cautions there is no assurance a definitive agreement will be finalized or that the transaction will close, and any deal would be subject to customary conditions and audited financials.
Aspire Biopharma Holdings, Inc. entered into a non-binding letter of intent to acquire 100% of the Driver Controls Systems business unit of Firefish Topco, LLC for an enterprise value of $30.0 million on a cash-free, debt-free basis, payable in cash at closing.
The LOI includes reciprocal break-up fees of $3.5 million under specified failure-to-close or bad-faith scenarios, as well as a 30-day no-shop period for the sellers, subject to possible extension. Most LOI terms are non-binding, and completion depends on negotiating and signing a definitive purchase agreement and satisfying closing conditions. Following a completed acquisition, the company plans to engage Lakewood & Company, LLC to provide management services for DCS, subject to a separate definitive management agreement.
Aspire Biopharma Holdings, Inc. is registering up to 159,090,906 shares of common stock for resale by existing investors, issuable upon conversion of its Series A Convertible Preferred Stock. These selling shareholders, not the company, will receive any proceeds from share sales.
The Preferred Stock supports up to $20 million of financing, with a first tranche of $11 million already funded on February 6, 2026 and a potential second tranche of up to $10 million contingent on conditions including effectiveness of this registration. The preferred converts at a variable price with a $0.264 per-share floor and a 4.99%–9.99% beneficial ownership cap, limiting how much common stock any holder can own after conversion.
Aspire is an early-stage biopharmaceutical and supplements company focused on patent-pending sublingual delivery technology. Its lead high-dose sublingual aspirin product has completed a positive pharmacokinetic clinical study showing faster blood availability and stronger platelet inhibition than standard oral aspirin, with a 505(b)(2) NDA submission targeted for 2026. The company is also advancing sublingual melatonin, vitamin, caffeine and other formulations, including its “Buzz Bomb” caffeine supplement line.
Aspire Biopharma Holdings, Inc. files an amended annual report to add its independent auditor’s report and related certifications, with no other changes to the original Form 10-K for the year ended December 31, 2025.
The company describes itself as an early-stage biopharmaceutical developer of patent-pending sublingual drug delivery technologies, led by a high‑dose sublingual aspirin program progressing toward a planned 505(b)(2) NDA submission. As of March 27, 2026, Aspire had 5,024,124 shares of common stock outstanding, and the aggregate market value of voting stock held by non‑affiliates was about $17.4 million as of December 31, 2025.